Virginia Physicians Use Elekta Software to Better Target Moving Tumors in Patients with Lung or Liver Cancer

NEWPORT NEWS, Va. and ATLANTA /PRNewswire/ — In
treatments of only the first handful of patients with lung or liver tumors,
Riverside & University of Virginia Radiosurgery Center (Newport News, Va.)
clinicians have demonstrated the dramatic benefit that Elekta’s Symmetry™
4D image guidance technology can provide for patients whose tumors move
with their breathing. Symmetry essentially yields a more distinct picture of
the tumor, without the blurring associated with breathing motion.

By having a clearer picture of the tumor position and its
motion, physicians have been able to improve their targeting of tumors, thereby
avoiding having to treat a larger margin of healthy tissue around the lesion. A
Symmetry scan is acquired just before treatment to ensure that the patient is
correctly positioned, and to visualize tumor movement.

“Symmetry scans give us clearer information about the
movement of the tumor, allowing us to increase the safety of treating our
patients by decreasing the dose to healthy tissues, while hopefully providing a
better clinical outcome,” according to Riverside
medical physicist Kelly Spencer.

Tumor motion in sharper focus

Before they began using the Symmetry feature in Elekta’s XVI package of IGRT
tools, Riverside clinicians were using sophisticated XVI 3D cone beam CT
(VolumeView™ CBCT) imaging technology integrated with their Elekta Synergy® S
to image tumors. These pre-treatment scans provide physicians with added
confidence in the margins that they have planned. Although seeing a target with
IGRT technology such as VolumeView has been a key clinical improvement, the
motion still created a blur that encompassed the tumor’s range of motion.

“For our current protocol, we would create an ITV
[internal target volume] to cover the blur we see on the VolumeView,”
Spencer says. “We began using Symmetry on a couple of patients with lower
lung lesions near the diaphragm where we would expect tumor motion to be an
issue. We were actually quite mesmerized by the images Symmetry provided. We
could clearly see the actual motion of the delineated tumor with respect to the
patient’s breathing.”

The same Symmetry benefit applied to a recent patient with a
liver tumor situated near the diaphragm. In this case, clinicians inferred
tumor motion by observing the movement of the liver with the patient’s
breathing.

“We wanted to use Symmetry to see how the superior
border of the liver moved, and what we observed was that it did not move simply
superior to inferior – there was almost a rolling pattern to the liver
motion,” Spencer recalls. “We knew that the liver didn’t necessarily
move symmetrically on CBCT scans, but it was harder to appreciate due to motion
artifact. This movement probably varies between patients, so that is an
excellent reason to use Symmetry to evaluate this motion on a case-by-case
basis.”

The extent of tumor motion as depicted in a Symmetry scan
helps clinicians confirm that the margins around the tumor that they applied
during the planning phase are as small as possible, thereby protecting healthy
uninvolved tissues.

“For example, The Radiation Therapy Oncology Group SBRT
Lung protocol criterion is 1.0 cm margins superior and inferior on the gross
tumor volume,” he notes. “With Symmetry we can potentially reduce the
standard margins and thereby decrease the dose to the uninvolved lung
tissues.”

Accounting for tumor motion is especially important for
patients with lung tumors, as Riverside’s
protocol calls for beam delivery while the patient is breathing freely.

“Many of our lung cancer patients are older, they often
have chronic obstructive pulmonary disease or emphysema, so their shortness of
breath and erratic breathing pattern makes them unsuited for breath hold
treatments or any sort of gating,” Spencer says.

He adds that eight out of 10 patients with lung tumors could
benefit from a Symmetry scan.

“We are very excited about our future with
Symmetry,” he says. “We expected to be able to see a clearer picture
of tumor motion, but we hadn’t appreciated how well we would see the motion in
all three dimensions. It hasn’t been just superior to inferior tumor motion;
Symmetry shows how a tumor can move anterior to posterior or left to right. In
that respect, Symmetry has really exceeded our initial expectations.”

*Approval of indications may vary between different
countries. Additional regulatory clearances may be required in some markets.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care. Stretching the
boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are
used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on the Nordic Exchange under the ticker EKTAb.
Website: www.elekta.com.

Posted by Sean Fenske, Editor-in-Chief, MDT